Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13600075 | 0.76 | CA12 (0.41) | CYP11B2CYP11B1CA12CA1CA2 | |
| SCHEMBL25823035 | 0.74 | CYP11B2 (0.35) | CYP11B2CYP11B1CYP19A1CYP2C9P2RX7 | |
| SCHEMBL25823094 | 0.72 | CYP11B2 (0.39) | CYP11B2CYP11B1CYP19A1CYP2C9P2RX7 | |
| SCHEMBL19120677 | 0.71 | AR (0.44) | — | |
| SCHEMBL18949738 | 0.70 | TSHR (0.49) | CYP11B2CA12CA1CA2CA9 | |
| SCHEMBL1016366 | 0.70 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP2C9CYP1A2 | |
| SCHEMBL26847571 | 0.69 | ELOVL1 (0.38) | CYP11B2 | |
| SCHEMBL18949731 | 0.68 | CA12 (0.47) | CA12CA1CA2CA9P2RX7 | |
| SCHEMBL1014042 | 0.68 | CYP11B2 (0.39) | CYP11B2CYP11B1CYP19A1CYP2C9CYP1A2 | |
| SCHEMBL1010921 | 0.67 | CYP11B2 (0.38) | CYP11B2CYP11B1CYP19A1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | CYP11B2 2148/4885CYP11B1 1972/4885CYP19A1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.